Glaucoma
Conditions
Keywords
Glaucoma, Collagen matrix, ologen, OculusGen, Trabeculectomy
Brief summary
The purpose of this study is to compare the safety and effectiveness of trabeculectomy with ologen (OculusGen) Biodegradable Collagen Matrix Implant and trabeculectomy without antifibrotic agents.
Detailed description
1. Study Objective: To determine the safety and effectiveness of the ologen (OculusGen) Biodegradable Collagen Matrix Implant in filtration surgery. The primary endpoint is to prove the effectiveness via the reduction of IOP, and the secondary endpoint is to prove the safety via the incidence of complications and adverse events. 2. Study Design: The study is designed as an open-label, randomized, parallel, comparative study. Patients who meet the inclusion/exclusion criteria and sign informed consent will be included. After enrollment, patients will be randomized into two groups: trabeculectomy with OculusGen implant or trabeculectomy without antifibrotics. 3. Follow-Up: There will be 7 post-operative and follow-up visits within 6 months of surgery: postoperative days 1, 7, 14, 30, 60, 90 and 180. A window of ± 7 days is allowed for the 30, 60, 90 day visits and ± 14 days for the 180 day visits. Further follow-up of subjects after the trial will be the responsibility of the investigator.
Interventions
Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
Sponsors
Pro Top & Mediking Company Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 30 years or over. * No previous intraocular operative surgery * Uncontrolled glaucoma, with failed medical and laser treatment, requiring trabeculectomy. * Subject able and willing to cooperate with investigation plan. * Subject able and willing to complete postoperative follow-up requirements. * Subject willing to sign informed consent form.
Exclusion criteria
* Known allergic reaction to porcine collagen. * Subject is on warfarin and discontinuation is not recommended. * Patient who has been diagnosed for one of following glaucoma: normal tension glaucoma, uveitic glaucoma, aphakia or pseudophakia glaucoma, neovascular glaucoma and other classified secondary glaucoma. * Participation in an investigational study during the 30 days proceeding trabeculectomy. * Ocular infection within 14 days prior to trabeculectomy. * Pregnant or breast-feeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the effectiveness via the reduction of IOP | 180 day |
Secondary
| Measure | Time frame |
|---|---|
| the safety via the incidence of complications and adverse events. | 180 day |
Countries
India
Outcome results
None listed